Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- About
FATE 
Fate Therapeutics Inc (FATE)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/05/2025: FATE (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
12 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $4.94
1 Year Target Price $4.94
| 3 | Strong Buy |
| 2 | Buy |
| 7 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 46.95% | Avg. Invested days 32 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 12/05/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 124.58M USD | Price to earnings Ratio - | 1Y Target Price 4.94 |
Price to earnings Ratio - | 1Y Target Price 4.94 | ||
Volume (30-day avg) 12 | Beta 2.35 | 52 Weeks Range 0.66 - 2.93 | Updated Date 12/5/2025 |
52 Weeks Range 0.66 - 2.93 | Updated Date 12/5/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.33 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-11-13 | When - | Estimate -0.3 | Actual -0.27 |
Profitability
Profit Margin - | Operating Margin (TTM) -1995.12% |
Management Effectiveness
Return on Assets (TTM) -23.85% | Return on Equity (TTM) -52.35% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -11594528 | Price to Sales(TTM) 17.46 |
Enterprise Value -11594528 | Price to Sales(TTM) 17.46 | ||
Enterprise Value to Revenue 20.39 | Enterprise Value to EBITDA -2.59 | Shares Outstanding 115352289 | Shares Floating 100820208 |
Shares Outstanding 115352289 | Shares Floating 100820208 | ||
Percent Insiders 1.77 | Percent Institutions 79.54 |
Upturn AI SWOT
Fate Therapeutics Inc
Company Overview
History and Background
Fate Therapeutics, founded in 2007, focuses on developing cell-based immunotherapies for cancer and immune disorders. It has pioneered the development of induced pluripotent stem cell (iPSC)-derived cell therapies.
Core Business Areas
- iPSC-Derived Cell Therapies: Develops off-the-shelf cell therapies from renewable master iPSC lines. Focuses on NK cell and T cell programs for cancer immunotherapy.
Leadership and Structure
Scott Wolchko serves as President and CEO. The company has a typical biotech structure with R&D, clinical development, manufacturing, and commercial functions.
Top Products and Market Share
Key Offerings
- FT596 (Off-the-shelf CAR NK cell therapy): An off-the-shelf CAR NK cell therapy targeting CD19 for B-cell lymphomas. It is currently in clinical trials. Competitors include autologous CAR-T therapies from companies like Gilead (Kite), Novartis, and Bristol Myers Squibb, as well as other allogeneic cell therapy developers. Precise market share data unavailable as still in clinical development. Expected to compete in NHL, CLL market which is estimated to be $11.1 billion (2023)
- FT516 (Off-the-shelf NK cell therapy): An off-the-shelf NK cell therapy engineered to maximize antibody-dependent cellular cytotoxicity (ADCC) to enhance cancer cell killing. Currently in clinical trials. The competitors include other NK cell therapies. Precise market share data unavailable as still in clinical development. This program targets hematological malignancies and solid tumors.
Market Dynamics
Industry Overview
The cell therapy market is rapidly growing, driven by advancements in immuno-oncology and regenerative medicine. The market is competitive, with numerous companies developing novel cell therapies.
Positioning
Fate Therapeutics is positioned as a leader in iPSC-derived cell therapies, differentiating itself from companies focused on autologous or other allogeneic approaches. It has a first-mover advantage in this specific segment.
Total Addressable Market (TAM)
The cell therapy market is projected to reach hundreds of billions of dollars. Fate is focused on the cancer immunotherapy TAM, which is substantial. Fate's position is in novel allogeneic cell therapy, a fast-growing and high-potential part of TAM.
Upturn SWOT Analysis
Strengths
- iPSC-derived cell therapy platform
- Off-the-shelf approach (allogeneic)
- Strong IP portfolio
- Potential for scalable manufacturing
- Clinical data showing promise
Weaknesses
- Clinical development risk
- Manufacturing complexities
- Competition from established CAR-T therapies
- Regulatory hurdles
- High cash burn rate
Opportunities
- Expanding into new cancer indications
- Partnering with larger pharmaceutical companies
- Developing combination therapies
- Addressing unmet medical needs
- Improving manufacturing efficiency
Threats
- Clinical trial failures
- Regulatory delays
- Competition from other cell therapy companies
- IP challenges
- Reimbursement challenges
Competitors and Market Share
Key Competitors
- GILD
- BMY
- NVS
- CRIS
Competitive Landscape
Fate Therapeutics has a unique iPSC-derived platform advantage, but faces competition from established CAR-T players and other allogeneic cell therapy developers. Its differentiation lies in the potential for off-the-shelf, scalable therapies.
Growth Trajectory and Initiatives
Historical Growth: Growth is primarily driven by pipeline advancement and clinical trial progress.
Future Projections: Future growth hinges on clinical trial success and potential commercialization of its cell therapy products. Analyst estimates vary widely.
Recent Initiatives: Focus on advancing clinical trials for FT596 and FT516, expanding manufacturing capabilities, and exploring new therapeutic targets.
Summary
Fate Therapeutics is an innovative biotech company pioneering iPSC-derived cell therapies. Its strengths are its unique platform and off-the-shelf approach, but clinical development risks and competition remain challenges. Continued progress in clinical trials and strategic partnerships will be crucial for future success. The company's financial performance is highly dependent on the success of its pipeline.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings (10-K, 10-Q)
- Analyst Reports
- ClinicalTrials.gov
- Press Releases
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Market share data is estimated and may not be precise. Investment decisions should be based on your own due diligence.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Fate Therapeutics Inc
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2013-10-01 | President, CEO & Director Dr. Bahram Valamehr M.B.A., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 181 | Website https://www.fatetherapeutics.com |
Full time employees 181 | Website https://www.fatetherapeutics.com | ||
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma; FT836 whiuch is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell programs include FT819 to treat systemic lupus erythematosus, and FT825 to treat solid tumors.It has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of solid tumors. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.